Notice of scheduled deliberation at the BNCT pharmaceutical affairs council. A partial change application to the marketing authorization for Steboronin\u00ae to include recurrent meningioma has been submitted and is scheduled for deliberation by the Council\u2019s Second Subcommittee. The impact on the fiscal year ending March 2027 is expected to be minimal.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4888","jir_company_name":"Stella Pharma Corporation","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-07","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4888-20261007-01.pdf","jir_short_summary":"Notice of scheduled deliberation at the BNCT pharmaceutical affairs council. A partial change application to the marketing authorization for Steboronin\u00ae to include recurrent meningioma has been submitted and is scheduled for deliberation by the Council\u2019s Second Subcommittee. The impact on the fiscal year ending March 2027 is expected to be minimal.","jir_summary":"### Key Points\nA partial change application to the marketing authorization for Steboronin\u00ae to include recurrent meningioma has been submitted. The Ministry of Health, Labour and Welfare has announced that this application is scheduled for deliberation by the Pharmaceutical Affairs and Medical Devices Council\u2019s Second Subcommittee. Measures to expand indications in the BNCT field continue, contributing to the company\u2019s growth strategy pillar of indication expansion. Deliberation results and future disclosures will be announced as appropriate.\n\n### Outlook and Impact\nThe impact on the fiscal year ending March 2027 is expected to be minimal, and additional disclosures may be made depending on the council\u2019s conclusion. The company will continue initiatives to expand indications and promote overseas deployment as efforts to broaden market and treatment options.","jir_financial_highlights":"Unknown: Unknown (Unknown)","jir_category":"","jir_hashtags":"#NoShareBuyback, #NoExecutivePersonnelChanges","jir_key_figures":"Unknown: No financial metrics disclosed other than company name and official title\nUnknown: Specific date\/time of the scheduled deliberation has been announced but numeric details are unspecified\nUnknown: The impact on the fiscal year ending March 2027 is described as minimal, but amounts are unspecified","jir_meta_title":"Stella Pharma Corporation \u2014 Scheduled Deliberation for Steboronin\u00ae for Recurrent Meningioma | October 2026","jir_meta_description":"Notice of a scheduled deliberation at the BNCT pharmaceutical affairs council. A partial change application to expand the indication of Steboronin\u00ae to recurrent meningioma is underway. Impact on FY March 2027 is expected to be minimal.","jir_og_title":"Scheduled Deliberation for Steboronin\u00ae for Recurrent Meningioma | October 2026","jir_og_description":"The Second Subcommittee of the Pharmaceutical Affairs and Medical Devices Council will deliberate on expansion of the indication for the BNCT therapeutic Steboronin\u00ae. Additional disclosures may follow depending on the deliberation outcome. Impact on FY results is expected to be minimal.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59263,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-128148","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n